A：AI and machine learning capabilities are advancing across businesses, which is anticipated to lead to nearly $1 billion in operating cost reductions in 2026. Over 80% of member calls are expected to leverage AI tools for faster and more accurate responses, allowing advocates to focus on enhancing the service experience.

A：Optum is implementing new pricing models for Optumrx to deliver greater transparency and cost-based reimbursements to pharmacies, removing reauthorization requirements for 180 drugs, and continuing to pass through 1% of drug rebates to customers. These measures are expected to drive a margin expansion of about 100 basis points in Optumrx.

A：The integration of AI-driven revenue cycle solutions with payment and financing capabilities could transform health care transactions. It is expected to reduce long-standing price friction, enhance growth and margins by expanding beyond transaction processing, and create new value pools for payers.

A：Optum Health's operating earnings growth of about 100 basis points is driven by a focus on integrated value-based care execution, particularly in markets with a strong presence and complementary wraparound services. This strategy has led to practices operating in this environment reducing total cost of care by up to 30% with high patient satisfaction.

A：The realignment of Optum's provider network and risk membership has led to a reduction in total cost of care, improved patient satisfaction, and a narrowing of the affiliated network to better serve patients with a more optimal alignment of physicians and services.

A：Optum plans to continue bringing the integrated value-based care approach back to its original purpose, with a focus on strong, transparent, consistent results and higher quality of care for patients while lowering system-wide costs. This will involve further progress and a journey back to solid operational execution and financial discipline.

A：The net charge of $2.5 billion in the quarter was primarily due to restructuring and other actions including contract reassessments, real estate rationalization, and workforce reductions. It also included a lost contract reserve for third-party contractual relationships that were structurally unprofitable and could not be exited for cycle reasons.

A：The financial results for the full year mentioned in the speech include revenues of nearly $448 billion, driven by script growth and domestic membership growth. The medical care ratio came in slightly better than expectations and the operating cost ratio was in line with management discipline and key investments. However, earnings were impacted by negative charge related to a loss contract reserve and higher than anticipated operating cost ratio due to employee incentives and funding to the United Health Foundation.

A：The expectations for 2026 include revenues of approximately $440 billion, net earnings of at least $17.10 per share, and adjusted net earnings greater than $17.10 per share. This outlook reflects anticipated operational improvements and margin stabilization as part of executing the long-term strategy.

A：The projected operating cost ratio for 2026 is 12.8% plus or minus 10 basis points, which is expected to reflect disciplined cost management, ongoing productivity initiatives, and the early benefits of investments in artificial intelligence.

A：The company's approach to capital and liquidity includes maintaining well-supported dividends by earnings and cash flow. It is expected that leverage will continue improving through the year, supported by strong cash generation and a more stable operating environment, with a goal to reach a long-term debt to capital target before the end of the year.

A：The three overarching themes the company is pursuing include a refocus back to the mission and culture, the urgent, thoughtful application of modern intelligent technologies, and methodically advancing greater trust and transparency.

A：The company plans to advance trust and transparency by publishing independent reviews of business practices and risk assessment in pharmacy services and care management, and by publishing results in areas of interest such as prior authorizations, claim approval rates, performance statistics, and rebate practices. This is in line with becoming more publicly accountable for performance and striving to improve it.

A：The company's confidence in meeting long-term targets is bolstered by performance improvements in various markets, including a large Texas market where they serve over 750,000 patients across over 50 clinics with strong outcomes. They have a 4.5-star health plan, a total cost of care that is approximately 30% better than competitors, patient satisfaction of 90%, strong provider retention, and margins already within their long-term target range. Another contributing factor is that 30% of mature value-based care patients are already within or above the target margin range.

A：The company expects some margin contraction in their Medicaid business due to ongoing rate dislocations and elevated medical trends. They anticipate rate increases in the low to mid-single digits for the year, which will continue to be below their medical trend, leading to some membership contraction as they manage the business for January 1. The current rates are somewhat in line with expectations and are expected to range between the low to mid-single digits for the year.

A：The implementation of the Inflation Reduction Act (IRA) has led to more even seasonal trending throughout the year in the Medicare Part D business. The way benefits are positioned on Part D, both for standalone PDP and MA-PD, reflects the evolution of the program and industry design, which is in line with the overall industry movement.

A：The impact of recent membership growth on earnings projections for 2026 is positive. A strong selling season combined with continued high 90s retention allowed the company to backfill about half of the membership loss from UHC. As a result, the company is positioned to deliver a modest 2% earnings growth in 2026, with core business earnings expected to return to the low double digits to high single digits.

A：The decision by 800 new clients to join OptumRX is attributed to several factors: strong performance across core businesses, growth in each business segment in the high single digits, and winning on affordability, transparency, and execution. OptumRX's commitment to affordability is demonstrated through negotiations with drug manufacturers and savings for members. Additionally, their commitment to transparency and provider-patient interaction is evidenced by high Net Promoter Scores (NPS) across various services. The removal of provider and patient abrasion through streamlining the prior authorization process also contributed to their appeal. Overall, the transformational vision, resonant offering, and execution by their team solidified the decision by these new clients to join.

A：The expected decline in commercial risk lives for 2026 is between 1.3 to 1.4 million. This decline is mainly attributed to the exchange business, with 500,000 lives expected to leave, while the remainder will result from general market decline, pricing posture, and migration to self-funded, level-funded small employer offerings.

A：For the exchange business in 2026, margins are expected to be in the script range plus or minus phi. The group business is anticipated to have a more positive margin, though specific figures are not provided.

A：Although it is not confirmed for 2027, the business is described as meaningfully stronger than a few months ago, with a focus on further strengthening it in 2026. Looking at the long term, United believes it can operate within its long-term growth rate margin of 13% to 16%, and the need for value-based care and solid organic growth make the long-term growth rate compelling. The potential for the enterprise to serve the healthcare marketplace and leverage AI-driven productivity and scale innovation is considered significant, supporting the view that growth rates have never been better.

A：The updated expectation for the growth rate in 2026 is 10%, which is higher than the actual growth of 7.5% in Medicare seen in 2025. The expectation for commercial growth is still around the historical trend line of approaching Ed.

A：Yes, the long-term margin target of 6 to 8% is still intact. This is supported by the performance of mature value-based cohorts, confidence in investments shaping up in 2026, and the strength of the integrated value-based care delivery system which is aligned with quality outcomes and cost efficiency.

A：The progress on the Optum turnaround has been positive, with better market portfolio decisions and improvements in the business portfolio. Value-based care is considered critical, and despite recent challenges, the long-term margin target remains unchanged, with expectations of modest earnings improvement in 2026. The support for value-based care initiatives and the integrated offering is emphasized, along with the unique delivery system that demonstrates value and quality outcomes.

A：Upcoming independent reviews by UNH in 2026 will focus on risk assessment accuracy and metrics, clinical policy accuracy, and pharmacy services. These reviews are part of efforts to advance trust and transparency, following strong showings in policies, procedures, and compliance in 2025. The aim is to continue improving governance and controls, particularly in relation to risk adjustment.